Breakthrough in Precision Cancer Therapy: Liver-Sparing in Early Studies Lehi, Utah — CancerVax, Inc., a pre-clinical biotechnology company, announced today that recent in-vitro studies demonstrate a significant reduction in liver toxicity for its universal cancer treatment platform. The findings address a long-standing challenge in oncology: protecting healthy liver tissue while delivering effective cancer-killing therapy. If…